Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating expenses:        
Research and development $ 1,629 $ 1,874 $ 3,010 $ 4,481
General and administrative 1,079 867 2,102 1,681
Operating loss (2,708) (2,741) (5,112) (6,162)
Other (income) expense:        
Governmental assistance - research incentives (65) (226) (180) (400)
Other income, net (178) (54) (51) (58)
Total other income (243) (280) (231) (458)
Loss before income tax expense (2,465) (2,461) (4,881) (5,704)
Income tax expense 9 8 18 17
Net loss (2,474) (2,469) (4,899) (5,721)
Other comprehensive income        
Unrealized gain on marketable securities (13) 8 27 11
Net loss and comprehensive loss $ (2,487) $ (2,461) $ (4,872) $ (5,710)
Basic and diluted net loss per share (in dollars per share) $ (0.17) $ (0.21) $ (0.36) $ (0.48)
Weighted average shares outstanding – basic and diluted (in shares) 14,139,074 11,979,401 13,623,400 11,968,200